SEC Form 4 · accession 0002061851-26-000006
Sionna Therapeutics, Inc. · SION
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Fitzpatrick
Officer — Chief Legal Officer
Period of report
Jul 6, 2026
Accepted (ET)
Jul 7, 2026 · 4:38 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002036042
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2026 | M | 10,250 | $6.11 | A | 10,250 | D | |
| Common StockF2 | Jul 6, 2026 | S | 10,250 | $43.5963 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $6.11 | Jul 6, 2026 | M | 10,250 | D | — | Jul 14, 2034 | Common Stock | 10,250 | 40,685 | D |
Explanation of responses
- F1This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.89 to $44.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F325% of the shares underlying this option vested on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.